Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15473232 | 0.85 | KDM1A (0.50) | KDM1AGAAALDH1A1PTGER1 | |
| SCHEMBL12401838 | 0.81 | LMNA (0.57) | LMNAMAPK1HTTKDM4EGAA | |
| SCHEMBL9967704 | 0.79 | KDM1A (0.56) | LMNAKDM1AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4721403 | 0.78 | PTGER1 (0.47) | LMNAMAPK1KDM1AKDM4EGAA | |
| SCHEMBL19533099 | 0.77 | MAPK1 (0.47) | LMNAMAPK1HTTKDM4EGAA | |
| SCHEMBL325648 | 0.77 | SCN4A (0.60) | LMNAMAPK1HTTKDM1AKDM4E | |
| SCHEMBL4720505 | 0.77 | PTGER1 (0.47) | LMNAMAPK1KDM1AKDM4EGAA | |
| SCHEMBL4721805 | 0.77 | KDM1A (0.46) | LMNAMAPK1KDM1AKDM4EGAA | |
| SCHEMBL14098678 | 0.76 | MRGPRX4 (0.46) | LMNAMAPK1KDM1AKDM4EALDH1A1 | |
| SCHEMBL3727775 | 0.76 | KDM1A (0.54) | LMNAKDM1AGAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133898-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100137310-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137310-A1 | RENIN INHIBITORS | REN, ACE, PRSS3 | LMNA 1313/4885MAPK1 2740/4885HTT 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.